Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

87 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Canadian Urological Association/Genitourinary Medical Oncologists of Canada consensus statement: Management of unresectable locally advanced and metastatic urothelial carcinoma.
Warren M, Kolinsky M, Canil CM, Czaykowski P, Sridhar SS, Black PC, Booth CM, Kassouf W, Eapen L, Mukherjee SD, Blais N, Eigl BJ, Winquist E, Basappa NS, North SA; GUMOC. Warren M, et al. Among authors: mukherjee sd. Can Urol Assoc J. 2019 Oct;13(10):318-327. doi: 10.5489/cuaj.6015. Can Urol Assoc J. 2019. PMID: 31059420 Free PMC article. No abstract available.
Randomized phase II trial of Custirsen (OGX-011) in combination with docetaxel or mitoxantrone as second-line therapy in patients with metastatic castrate-resistant prostate cancer progressing after first-line docetaxel: CUOG trial P-06c.
Saad F, Hotte S, North S, Eigl B, Chi K, Czaykowski P, Wood L, Pollak M, Berry S, Lattouf JB, Mukherjee SD, Gleave M, Winquist E; Canadian Uro-Oncology Group. Saad F, et al. Among authors: mukherjee sd. Clin Cancer Res. 2011 Sep 1;17(17):5765-73. doi: 10.1158/1078-0432.CCR-11-0859. Epub 2011 Jul 25. Clin Cancer Res. 2011. PMID: 21788353 Clinical Trial.
A phase II study of cediranib (AZD 2171) in treatment naive patients with progressive unresectable recurrent or metastatic renal cell carcinoma. A trial of the PMH phase 2 consortium.
Sridhar SS, Mackenzie MJ, Hotte SJ, Mukherjee SD, Tannock IF, Murray N, Kollmannsberger C, Haider MA, Chen EX, Halford R, Wang L, Ivy SP, Moore MJ. Sridhar SS, et al. Among authors: mukherjee sd. Invest New Drugs. 2013 Aug;31(4):1008-15. doi: 10.1007/s10637-013-9931-1. Epub 2013 Jan 26. Invest New Drugs. 2013. PMID: 23354849 Clinical Trial.
Management of small cell carcinoma of the bladder: Consensus guidelines from the Canadian Association of Genitourinary Medical Oncologists (CAGMO).
Moretto P, Wood L, Emmenegger U, Blais N, Mukherjee SD, Winquist E, Belanger EC, Macrae R, Balogh A, Cagiannos I, Kassouf W, Black P, Czaykowski P, Gingerich J, North S, Ernst S, Richter S, Sridhar S, Reaume MN, Soulieres D, Eisen A, Canil CM. Moretto P, et al. Among authors: mukherjee sd. Can Urol Assoc J. 2013 Jan-Feb;7(1-2):E44-56. doi: 10.5489/cuaj.220. Can Urol Assoc J. 2013. PMID: 23671508 Free PMC article. No abstract available.
Management of carcinoma of the penis: Consensus statement from the Canadian Association of Genitourinary Medical Oncologists (CAGMO).
Richter S, Ruether JD, Wood L, Canil C, Moretto P, Venner P, Gingerich J, Emmenegger U, Eisen A, Zalewski P, Joshua A, Mukherjee SD, Heng D, Czaykowski P, Soulieres D, Blais N, Rendon R, Fleshner N, Crook JM, Sridhar SS. Richter S, et al. Among authors: mukherjee sd. Can Urol Assoc J. 2013 Nov-Dec;7(11-12):E797-811. doi: 10.5489/cuaj.1794. Can Urol Assoc J. 2013. PMID: 24475001 Free PMC article. No abstract available.
A randomized phase II study of cediranib alone versus cediranib in combination with dasatinib in docetaxel resistant, castration resistant prostate cancer patients.
Spreafico A, Chi KN, Sridhar SS, Smith DC, Carducci MA, Kavsak P, Wong TS, Wang L, Ivy SP, Mukherjee SD, Kollmannsberger CK, Sukhai MA, Takebe N, Kamel-Reid S, Siu LL, Hotte SJ. Spreafico A, et al. Among authors: mukherjee sd. Invest New Drugs. 2014 Oct;32(5):1005-16. doi: 10.1007/s10637-014-0106-5. Epub 2014 May 3. Invest New Drugs. 2014. PMID: 24788563 Free PMC article. Clinical Trial.
Evaluation of second-line and subsequent targeted therapies in metastatic renal cell cancer (mRCC) patients treated with first-line cediranib.
Richter S, Seah JA, Pond GR, Gan HK, Mackenzie MJ, Hotte SJ, Mukherjee SD, Murray N, Kollmannsberger C, Heng D, Haider MA, Halford R, Ivy SP, Moore MJ, Sridhar SS. Richter S, et al. Among authors: mukherjee sd. Can Urol Assoc J. 2014 Nov;8(11-12):398-402. doi: 10.5489/cuaj.2426. Can Urol Assoc J. 2014. PMID: 25553152 Free PMC article.
87 results